Not found, error 404
The page you are looking for no longer exists. Perhaps you can return back to the site's homepage and see if you can find what you are looking for. Or, you can try finding it by using the search form below.
Pages:
- 2020 GBMA Code of Practice Training Workshop Quiz
- 2021 GBMA Code of Practice Training Workshops Feedback Survey
- 2021 GBMA Supply Chain Questionnaire
- 2022 GBMA Code of Practice Training Workshop Quiz
- 2022 GBMA Code of Practice Training Workshops Feedback Survey
- 2023 GBMA Code of Practice Training Workshops Quiz
- A new name for a new era
- About GBMA
- Advocacy
- Biosimilars
- COVID-19 Virus
- Extended Strategic Agreement
- GBMA Code of Practice
- GBMA Education
- Generic Medicines Facts
- Key Industry Facts
- Links
- New 5-year Strategic Agreement
- Privacy Policy
- Site Map
- Strategic agreement recognises the important role of generic and biosimilar medicines in delivering affordable healthcare
- Test Home
- Historical Event Reporting
- Lodging a complaint
- Home
Categories:
Authors:
- Admin (50)
- GBMA (7)
- GBMA Admin (41)
Monthly:
- March 2024
- January 2024
- November 2023
- September 2023
- July 2023
- June 2023
- May 2023
- March 2023
- November 2022
- October 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- December 2021
- November 2021
- October 2021
- September 2021
- May 2021
- March 2021
- February 2021
- December 2020
- October 2020
- September 2020
- July 2020
- May 2020
- April 2020
- March 2020
- October 2019
- September 2019
- August 2019
- July 2019
- May 2019
- April 2019
- March 2019
- September 2018
- August 2018
- June 2018
- April 2018
- February 2018
- October 2017
- September 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- December 2016
- November 2016
- September 2016
- July 2016
- May 2016
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- May 2015
- March 2015
- February 2015
- December 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- March 2014
- February 2014
- June 2013
- February 2013
Recent Posts:
- The 2024 GBMA Board – New appointments at a time of significant reform of Australia’s medicine policy
- IGBA announces leadership change
- IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care
- Neo Health joins GBMA under new membership tier
- GBMA welcomes Teva Pharma to its growing membership base
- New member, Pearce IP, shares GBMA mission to secure access to affordable medicines
- Federal Budget 2023: patient benefits at the centre of healthcare reforms
- Peak body for affordable medicines welcomes new board members at a pivotal time for the health budget and medicine policy reforms
- IGBA reiterates its yearly call to join the biosimilars movement on advancing access
- Federal budget delivers for Australian patients GBMA welcomes funding for cheaper medicines
- GBMA welcomes new member at a pivotal time in medicine policy
- Peak body for affordable medicines welcomes the announcement of Mark Butler as the new Minister for Health and Aged Care – Prioritising patients is the shared mission
- 2022 Biosimilar Awareness Week: 30 May – 3 June
- Health Minister, Greg Hunt MP and Shadow Health Minister, Mark Butler MP both applaud the role of the GBMA Strategic Agreement for the security of the supply of vital medicines
- Health Minister, Greg Hunt MP and Shadow Minister, Mark Butler MP confirmed as VIP speakers at the GBMA Industry Budget Week luncheon
- Australia’s peak body for affordable medicines welcomes a new board member
- GBMA welcomes new member at a critical time in medicine policy
- ACCC helps to further protect Australians further protected against medicine shortages caused by COVID-19
- GBMA welcomes a new member
- Minister for Health & Ageing, the Hon Greg Hunt MP, applauded for two decades of public service
- Australians soon to have greater protection from medicine shortages Herald landmark legislation secures supply of vital medicines
- A protection against medicine shortages in sight with the passage of a landmark Bill
- IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access
- Affordable medicines Industry heralds landmark Bill to protect Australians against medicine shortages
- Medicines industry continues to protect Australians from medicine shortages – ACCC extends approval for ongoing collaboration
- Affordable medicine supplies secured for all Australian patients Landmark Strategic Agreement to mitigate against medicine shortages
- GBMA welcomes a new board member Medicine shortages, security of supply and affordability remain a key focus for 2021-22
- Budget 2021-22: A Budget for the times – GBMA welcomes the boost in funding for health
- Government extends the GBMA Education biosimilar education campaign
- Patients and economy to benefit from ‘medicine manufacturing’ roadmap
- Active Ingredient Prescribing – a game changer for patients: Prescription reforms to further support patient safety
- Announcement of Independent Chair
- Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists
- IGBA Launches First Global Biosimilars Week
- Budget 2020-21 – Australia’s ‘pandemic’ budget prioritises the needs of patients
- Australian patients must be able to access their medicines without undue delay
- Australian patients to benefit from ongoing collaboration between peak medicine bodies
- 2020 Biosimilar Awareness Week – Over half a million Australians reached
- Biosimilar Awareness Week – Federal Health Minister announces official opening for 2020
- Medicines Australia and the Generic & Biosimilar Medicines Association granted interim authorisation by the ACCC
- COVID19 Global Pandemic – Joint Position Statement by Medicines Australia and the Generic and Biosimilar Medicines Association
- The supply of vital medicines is our priority
- GBMA welcomes Fresenius Kabi Australia
- Federal Health Minister, Greg Hunt MP encourages healthcare sector to embrace biosimilar medicines.
- GBMA welcomes new appointment to the Board
- The Hon Greg Hunt MP, Minister for Health, to deliver keynote address at GBMA Education Biosimilar Forum and Workshop
- As focus grows for biosimilars, GBMA welcomes its newest member Celltrion
- GBMA welcomes Minister Hunt’s return to the Health portfolio
- Budget 2019-20 – Budget spending on health and new medicines a welcome investment in the health of Australians
- Health Minister Announces Details of 2019 Biosimilar Week
- Peak body for Generic and Biosimilar medicines welcomes legislation to inform patients about medicine shortages
- GBMA Education Commences 2018-2019 Grant Activities
- GBMA appoints project manager to lead the delivery of its Biosimilar Education Grant initiatives
- IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly
- Biosimilar Educational Grant awarded to GBMA Education
- GBMA announcement of new Chair
- GBMA announces the appointment of new CEO
- Belinda Wood to leave GBMA
- GBMA welcomes newest member – Juno Pharmaceuticals
- Pharmaceutical IP reform welcomed however complex issues remain
- Report lists all new generic and biosimilar medicines in 2016
- Budget 2017: GBMA welcomes initiatives to increase the use of affordable medicines
- Biosimilar naming – why changing the way we name biosimilar medicines won’t fix the problem some think we have.
- Misleading Grattan Institute Report risks ongoing supply of everyday medicines to Australian families
- Another infliximab biosimilar highlights need for uptake
- Prominent UK specialist to share biosimilar experience – health system savings and expanded patient access to the latest treatments
- GBMA welcomes Health Minister’s plans to streamline medicines regulation
- Biosimilar etanercept approval great news for Australian patients
- Budget 2016: Significant PBS savings and regulatory improvements confirmed
- Longer patents do not incentivise innovation or attract R&D to Australia
- Government and GBMA agree policy priorities for PBS and industry viability
- TPP finalised with no extension to data exclusivity for medicines: GBMA
- May Conference 2015
- Biosimilar infliximab approval great news for Australian patients
- GBMA welcomes PBS listing of biosimilar infliximab
- Allan Tillack Chair of GBMA
- A new name for a new era
- ‘A stronger, more focussed organisation’ Mark Crotty steps down as GMiA Chair
- GMiA welcomes new member – Amneal Pharmaceuticals
- Strategic agreement recognises the important role of generic and biosimilar medicines in delivering affordable healthcare
- GMiA welcomes the PBAC consideration of “a” flagging biosimilars, and the PBS listing of the first biosimilar insulin.
- GMiA launches a Guide to Biosimilars
- Biosimilar infliximab launch in EU is a great sign for Australian patients: GMiA
- GMiA welcomes new Minister for Health, Sussan Ley
- GMiA announces Belinda Wood as new CEO
- GMiA welcomes efficient patient access to affordable medicines
- Generic Medicines Manufacturing keeps Australia healthy – A fair go will keep it viable –
- Kate Lynch to step down as CEO of GMiA
- GMiA welcomes new member – Sandoz
- Congratulations to Prof Jane Halton on her new appointment
- Recognition of ongoing generic medicines savings
- The Commission’s Nuclear Option to attack the PBS is Madness
- GMiA welcomes the release of the Pharmaceutical Patent Review
- GMiA calls on government to think before irreversible damage occurs to the generic medicines industry
- Setting the record straight: PBS expenditure is in decline
- Media Enquiries
- Members Login
- Members information